Mutated KRAS Is an Independent Negative Prognostic Factor for Survival in NSCLC Stage III Disease Treated with High-Dose Radiotherapy

Table 4

Univariate Cox-analyses.

Covariate	Number of patients	HR	95% confidence interval	𝑃 value
KRAS
Not mutated	47	1
Mutated	19	2.32	1.27–4.26	0.006
Gender
Males	38	1
Females	31	0.68	0.38–1.21	0.19
Age	69	0.99	0.96–1.03	0.67
PS
0	36	1
1	33	1.42	0.80–2.51	0.23
Stage
IIIa	18	1
IIIb	49	1.99	0.96–4.14	0.06
Weight loss
<5%	49
≥5%	20	1.79	0.98–3.27	0.06
Study
RAKET	35	1
Satellite	34	0.98	0.56–1.73	0.95